CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Viatris Q3 adjusted EPS beats estimates; hikes forecast

By Reuters News


Overview

  • Healthcare company's Q3 revenue was flat yr/yr and missed analyst expectations

  • Adjusted EPS for Q3 rose 6% and beat analyst expectations

  • Company raised 2026 financial guidance midpoints for all key metrics


Outlook

  • Viatris raises 2026 total revenue guidance midpoint to $14.8 bln from $14.75 bln

  • Company lifts 2026 adjusted EBITDA guidance midpoint to $4.5 bln from $4.4 bln

  • Viatris increases 2026 adjusted EPS guidance midpoint to $2.60 from $2.52


Result Drivers

  • SUPPLY CONSTRAINTS AND COMPETITION - Co said supply constraints in Europe and Emerging Markets and increased competition offset growth from new products and Greater China

  • NEW PRODUCT SALES - Co said new product sales contributed to revenue, primarily in Developed Markets

  • GREATER CHINA BRANDS - Co said continued strength in Greater China brands supported revenue


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$3.75 bln

$3.79 bln (8 Analysts)

Q3 Adjusted EPS

Beat

$0.71

$0.64 (9 Analysts)

Q3 Loss Per Share

$0.28

Q3 Net Loss

$325.30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Viatris Inc. is $20.00, about 4.1% above its November 4 closing price of $19.22

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago


Reuters Recommended Reads

  • Nov 3 - Henry Schein Q3 sales slightly miss, raises 2026 profit outlook

  • Nov 4 - Perrigo Q3 sales slightly beat expectations on market share gains

  • Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.